This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.
Age ≥ 18 years;
American Society of Anesthesiologists (ASA) physical status I-III;
Body mass index (BMI) 18-30 kg/m²;
Scheduled for elective video-assisted thoracoscopic surgery (VATS) lobectomy, segmentectomy, or wedge resection;
Severe systemic diseases, such as cardiovascular, hepatic, or renal abnormalities, or poor pulmonary function;
Subjects with cognitive dysfunction or psychological disorders;
History of previous esophageal or gastric surgery;
Hypersensitivity to acupuncture or any study medications;